Related Experiment Video
Updated: May 20, 2026
10:28
Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
Published on: January 22, 2018
Targeting STAT3 in gastric cancer
Andrew S Giraud1, Trevelyan R Menheniott, Louise M Judd
1Murdoch Childrens Research Institute, Royal Childrens Hospital, Parkville, Australia. andrew.giraud@mcri.edu.au
Expert Opinion on Therapeutic Targets
|July 28, 2012
Summary
Signal transducer and activator of transcription 3 (STAT3) activation drives gastric cancer. Targeting STAT3 or its upstream regulators may prevent stomach cancer development and progression.
Area of Science:
- Oncology
- Molecular Biology
- Gastroenterology
Background:
- Signal transducer and activator of transcription 3 (STAT3) is a crucial transcription factor regulating gene expression.
- Dysregulated STAT3 activation is implicated in inflammation and cellular transformation, particularly in epithelial cancers.
- STAT3 plays a significant role in the initiation and progression of gastric cancer.
Purpose of the Study:
- To review the role of STAT3 in gastric cancer initiation and progression.
- To emphasize STAT3 activation by cytokines in gastric cancer.
- To discuss therapeutic strategies targeting STAT3 and its upstream drivers.
Main Methods:
- Review of STAT3 signaling mechanics in gastric tumorigenesis.
- Analysis of upstream regulators of STAT3, including Helicobacter pylori infection.
- Examination of STAT3-activated genes promoting transformation and progression.
- Discussion of STAT3 and cytokine inhibitors as therapeutics.
Main Results:
- Constitutive STAT3 activation promotes gastric tumor development in human and mouse models.
- Upstream regulators, including cytokines and H. pylori, contribute to STAT3 activation.
- STAT3-activated genes are critical for cancer transformation and progression.
Conclusions:
- Chronic STAT3 activation is a key event in gastric cancer induction and progression.
- Targeting gastric epithelial STAT3 or specific signaling pathways (IL-11Rα/gp130, EGFR) may prevent gastric carcinogenesis.
- Therapeutic inhibition of STAT3 signaling offers a promising strategy for gastric cancer prevention.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...